Lumos Pharma, Inc.
NASDAQ: LUMO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard J. Hawkins
- Employees
- 30
- Headquarters
- Austin, United States
- IPO year
- 2011
- Market cap
- $37.5M
- Website
- https://www.lumos-pharma.com
Loading LUMO…
Loading profile data…Frequently asked questions about LUMO
What does Lumos Pharma, Inc. (LUMO) do?
Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug...
Where does LUMO trade?
Lumos Pharma, Inc. (LUMO) trades on the NASDAQ Global Market.
What sector is LUMO in?
Lumos Pharma, Inc. (LUMO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lumos Pharma, Inc.?
Richard J. Hawkins is the chief executive officer of Lumos Pharma, Inc. (LUMO).
Where is Lumos Pharma, Inc. headquartered?
Lumos Pharma, Inc. is headquartered in United States.
Does LUMO pay a dividend?
Lumos Pharma, Inc. (LUMO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LUMO go public?
Lumos Pharma, Inc. (LUMO) completed its initial public offering in 2011.